Atara Q1 2023 Earnings Report
Key Takeaways
Atara Biotherapeutics reported a net loss of $74.8 million for Q1 2023, with cash, cash equivalents, and short-term investments totaling $205.4 million. The company believes its current cash resources will fund planned operations into Q2 2024. Discussions with the FDA regarding tab-cel are progressing, and the first patients in Europe have been treated with EBVALLO following the transfer of EC Marketing Authorization to Pierre Fabre.
First patients in Europe treated with EBVALLO following transfer of EC Marketing Authorization to Pierre Fabre.
Discussions with FDA progressing regarding tab-cel.
ATA188 Phase 2 EMBOLD study primary data readout on-track for October 2023.
ATA3219 IND filing anticipated end of Q2 2023.
Atara
Atara
Forward Guidance
Atara believes that its cash and investments as of March 31, 2023, will be sufficient to fund the Company’s planned operations into Q2 2024